Novo Nordisk’s metabolic juggernaut semaglutide is known to work in chronic kidney disease – but the group appears to want a back-up plan. 

The COVID-19 pandemic drove huge shifts in clinical trial practice and the transformation is expected to continue even after the global health emergency abates. Industry leaders sharing their predictions around clinical development homed in on decentralized trials, digitization and data tools as key topics for 2022.

Currently, people with severe hearing loss are treated with conventional hearing aids, which have less than a 50% success rate due to such problems as feedback and discomfort. OtoKinetics Inc. hopes to increase that efficacy rate to at least 90% with its Krescendo implant, a titanium device about the size of a grain of rice that is inserted into the cochlea.

Currently, people with severe hearing loss are treated with conventional hearing aids, which have less than a 50% success rate due to such problems as feedback and discomfort. OtoKinetics Inc. hopes to increase that efficacy rate to at least 90% with its Krescendo implant, a titanium device about the size of a grain of rice that is inserted into the cochlea.